CYTOSORBENTS CORPORATION — Revenue by Fiscal Year
15 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/0e3001dc-87e9-4d7d-99a3-82071f138460/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $37.1M | 2025-01-01 – 2025-12-31 | evidence 0001104659-26-036451 |
| FY 2024 | $35.6M | 2024-01-01 – 2024-12-31 | evidence 0001104659-26-036451 |
| FY 2023 | $31.1M | 2023-01-01 – 2023-12-31 | evidence 0001410578-25-000591 |
| FY 2022 | $34.7M | 2022-01-01 – 2022-12-31 | evidence 0001410578-23-000234 |
| FY 2021 | $43.2M | 2021-01-01 – 2021-12-31 | evidence 0001410578-22-000331 |
| FY 2020 | $41.0M | 2020-01-01 – 2020-12-31 | evidence 0001104659-21-033790 |
| FY 2019 | $24.9M | 2019-01-01 – 2019-12-31 | evidence 0001104659-20-029712 |
| FY 2018 | $22.5M | 2018-01-01 – 2018-12-31 | evidence 0001104659-20-029712 |
| FY 2017 | $15.2M | 2017-01-01 – 2017-12-31 | evidence 0001104659-20-029712 |
| FY 2016 | $8.2M | 2016-01-01 – 2016-12-31 | evidence 0001144204-19-012774 |
| FY 2015 | $4.8M | 2015-01-01 – 2015-12-31 | evidence 0001144204-16-086916 |
| FY 2014 | $4.1M | 2014-01-01 – 2014-12-31 | evidence 0001144204-15-020124 |
| FY 2013 | $5.9M | 1997-01-22 – 2014-03-31 | evidence 0001144204-14-030424 |
| FY 2012 | $2.8M | 1997-01-22 – 2013-03-31 | evidence 0001144204-13-029672 |
| FY 2011 | $53.0k | 1997-01-22 – 2012-03-31 | evidence 0001144204-12-029748 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
CYTOSORBENTS CORPORATION — all facts · Net Income · Operating Income